TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

(2019) William D Tap et al.   LANCET

Antagonizing SET augments the effects of radiotherapy in hepatocellular carcinoma through reactivating PP2A-mediated AKT downregulation

(2018) Chao-Yuan Huang et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells

(2017) Chun-Yu Liu et al.   EUROPEAN JOURNAL OF CANCER

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

(2017) Man-Hsin Hung et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer

(2016) Daniela Achkova et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Macrophage Metabolism Shapes Angiogenesis in Tumors

(2016) Alberto Mantovani et al.   Cell Metabolism

Phosphatase PP2A is requisite for the function of regulatory T cells

(2016) Sokratis A Apostolidis et al.   NATURE IMMUNOLOGY

The role of microglia and macrophages in glioma maintenance and progression

(2016) Dolores Hambardzumyan et al.   NATURE NEUROSCIENCE

Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential

(2016) M-H Hung et al.   ONCOGENE

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy

(2015) Jacques F.A.P. Miller et al.   CANCER CELL

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy

(2015) J. Escamilla et al.   CANCER RESEARCH

CSF-1/CSF-1R targeting agents in clinical development for cancer therapy

(2015) Carola H Ries et al.   CURRENT OPINION IN PHARMACOLOGY

Single cell tuning of Myc expression by antigen receptor signal strength and interleukin-2 in T lymphocytes

(2015) G. C. Preston et al.   EMBO JOURNAL

The interaction of anticancer therapies with tumor-associated macrophages

(2015) Alberto Mantovani et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

(2015) Philippe A Cassier et al.   LANCET ONCOLOGY

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

(2015) William D. Tap et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer prevention and therapy through the modulation of the tumor microenvironment

(2015) Stephanie C. Casey et al.   SEMINARS IN CANCER BIOLOGY

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

Comprehensive Overview of the Structure and Regulation of the Glucocorticoid Receptor

(2014) Sofie Vandevyver et al.   ENDOCRINE REVIEWS

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

CSF-1 Receptor Signaling in Myeloid Cells

(2014) E. R. Stanley et al.   Cold Spring Harbor Perspectives in Biology

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A

(2014) H-C Yu et al.   Cell Death & Disease

Macrophage Regulation of Tumor Responses to Anticancer Therapies

(2013) Michele De Palma et al.   CANCER CELL

Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity

(2012) Kuen-Feng Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY

c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells

(2012) Zuqin Nie et al.   CELL

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteasomal degradation unleashes the pro-death activity of androgen receptor

(2010) Bradley Godfrey et al.   CELL RESEARCH

A CSF-1 Receptor Phosphotyrosine 559 Signaling Pathway Regulates Receptor Ubiquitination and Tyrosine Phosphorylation

(2010) Ying Xiong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

(2010) K-F Chen et al.   ONCOGENE

A Myc-regulated transcriptional network controls B-cell fate in response to BCR triggering

(2009) Jernej Murn et al.   BMC GENOMICS

Proteasome Inhibition Blocks Ligand-Induced Dynamic Processing and Internalization of Epidermal Growth Factor Receptor via Altered Receptor Ubiquitination and Phosphorylation

(2009) A. H. Kesarwala et al.   CANCER RESEARCH

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation

(2009) Kuen-Feng Chen et al.   JOURNAL OF HEPATOLOGY